Therefore, the in vivo effects of ASPHD1 on glioma progression observed here should be interpreted with caution, and future studies incorporating orthotopic intracranial models will be important to validate these findings under more physiologically relevant conditions. This evidence concerns the gene ASPHD1 and central nervous system cancer.